Abstract
While discovery scientists are interested in proof-of-concept data, regulators seek key safety data prior to advancing new drug candidates into first-in-human (FIH) clinical trials. Safety as well as therapeutic activity data continues to be collected and evaluated at each subsequent clinical trial stage of a program to gain proof of concept. This requires clear research and development targets to help guide the development pathway to provide phase-appropriate investigational new drug (IND) submissions.
In early discovery a customized development target product profile (dTPP) describing the key attributes of the proposed product is recommended. This dTPP defines the important aspects of the discovery target that guide the development program, and as it evolves, it becomes aligned with what regulatory reviewers have outlined as the key information for ultimate approval of the proposed product. These details provide scaffolding for a development pathway with appropriate regulatory targets and a foundation for the initial IND submission. The IND is the detailed description of the sponsor’s safety data, clinical study design, and drug product.
The goal of early studies in humans is the generation of sufficient data to transition to the next critical milestone and eventually to a safe, therapeutically beneficial, and therefore marketable drug product. Ultimately, this necessitates developing a product that keeps all stakeholders in mind: the innovator, the patient or end user, and regulators. Essential to achieving that goal is a strong foundation that is described in the IND.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Gold, L., Phelps, K. (2017). Regulatory Aspects at the Drug Discovery Development Interface. In: Bhattachar, S., Morrison, J., Mudra, D., Bender, D. (eds) Translating Molecules into Medicines. AAPS Advances in the Pharmaceutical Sciences Series, vol 25. Springer, Cham. https://doi.org/10.1007/978-3-319-50042-3_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-50042-3_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-50040-9
Online ISBN: 978-3-319-50042-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)